{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-004872","form_type":"8-K","ticker":"NDRA","cik":"0001681682","company_name":"ENDRA Life Sciences Inc.","filed_at":"2023-04-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.022050+00:00","generated_at":"2026-06-17T00:47:05.633214+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"ENDRA Life Sciences reports preliminary Q1 2023 net loss of $2.8M; no revenue","bullets":["Expects no revenue for Q1 2023, consistent with Q1 2022.","Net loss approximately $2.8M, improving from $2.9M loss in prior year.","Cash and cash equivalents $2.4M; total assets $6.7M; working capital $4.3M.","Filed S-1/A for underwritten public offering of common stock and warrants."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-004872","json":"https://secwatch.observer/filing/0001654954-23-004872.json","markdown":"https://secwatch.observer/filing/0001654954-23-004872.md","text":"https://secwatch.observer/filing/0001654954-23-004872.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681682/000165495423004872/0001654954-23-004872-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681682/000165495423004872/ndra_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T00:47:05.633214+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6376e3a77c469215d7096ee101d9b0dc64f0f66e","claim":"ENDRA Life Sciences Inc. reported the quarter ended March 31, 2023 results: revenue no revenue, net income net loss of approximately $2.8 million.","evidence_excerpt":"We expect no revenue for the quarter ended March 31, 2023 and did not have revenue for the quarter ended March 31, 2022. We expect to record a net loss of approximately $2.8 million for the quarter ended March 31, 2023, compared to a net loss of approximately $2.9 million for the quarter ended March 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1681682/000165495423004872/0001654954-23-004872-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Revenue","value":"no revenue"},{"label":"Net income","value":"net loss of approximately $2.8 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}